The Protective Effects of Bevacizumab in Bleomycin-Induced Experimental Scleroderma

Creative Commons License

KOCA S. S., Özgen M., Dagli A. F., GÖZEL N., ÖZERCAN İ. H., Isik A.

ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, cilt.25, sa.2, ss.249-253, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.17219/acem/32484
  • Dergi Adı: ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.249-253
  • Anahtar Kelimeler: bevacizumab, scleroderma, dermal fibrosis, VEGF, MICROVASCULAR ENDOTHELIAL-CELLS, SYSTEMIC-SCLEROSIS, GROWTH-FACTOR, ANGIOGENESIS, DIFFERENTIATION, PATHOGENESIS, DISEASE, ULCERS
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Background. The capillary networks are less dense and have irregular structures in scleroderma. These abnormalities result in lower capillary blood flow causing severe tissue hypoxia, which is a major stimulus for angiogenesis. However, current knowledge about compensatory angiogenesis is ambiguous in scleroderma. Bevacizumab is an inhibitor of vascular endothelial growth factor (VEGF).